About US
Contact us
-
Mylan CEO Bresch set to exit after years of controversy—and one last big dealDuring Mylan CEO Heather Bresch's 28-year stint there, the company has utterly transformed into a generics giant—and courted controversy along the way. And now, Bresch says she's stepping aside to cl2019/7/26
-
Deja vu? Pharma ad tax deduction faces threats—again—in Congress, on the trailPharma's advertising tax deduction is back on the chopping block, both in Congress and on the 2020 campaign trail. Last week, as a Senate drug-pricing reform bill made its way through the Finance Com2019/7/26
-
Pfizer's big split is finally here, thanks to a giant generics merger with MylanLooks like consumer health isn’t the only franchise Pfizer is looking to shed. In a payoff for years of split-up talk, thepharma giant's got hive-off plans for its generics business, too. And those p2019/7/25
-
Red flag upgrade for Pfizer: FDA limits Xeljanz in colitis, slaps black box on labelFor Pfizer’s blockbuster immunology drug Xeljanz, an FDA safety communication has now turned into a boxed warning. And forget the drug's approval as a first-line ulcerative colitis treatment, at leas2019/7/25
-
Vertex's planned CEO handoff could signal stagnant growth to come: analystSuccession planning is usually nothing to balk at—in fact, it’s considered responsible governance, particularly at a fast-growing company like Vertex Pharmaceuticals. But could Vertex'splan to move C2019/7/24
-
AstraZeneca's Lynparza scores limited NICE backing for new first-line maintenance useWith competitors racking up new indications and data wins, AstraZeneca’s Lynparza is looking to keep its lead in the PARP inhibitor field. England’s cost watchdog delivered a leg up Friday with a new2019/7/24
-
Novartis' Entresto flops crucial heart failure trial, imperiling $5B sales goalCardiovascular med Entresto’s blockbuster turn in 2018 was a long time coming for Novartis, which held on toa $5 billion vision for the drug even as its launch lagged. But those dreams took another h2019/7/23
-
Mylan CEO Bresch set to exit after years of controversy—and one last big dealDuring Mylan CEO Heather Bresch's 28-year stint there, the company has utterly transformed into a generics giant—and courted controversy along the way. And now, Bresch says she's stepping aside to cl2019/7/23
-
DOJ indicts 2nd opioid distributor for role in illegally pushing pills despite warning signsWith federal scrutiny mounting on claims it profiteered from the nation’s opioid epidemic, Ohio-based Miami-Luken shuttered its doors for good last year. But if the former company’s leaders thought t2019/7/22
-
AstraZeneca to shell out £12M in severance dispute with workers at former England plantWhen AstraZeneca sold its Avlon, England plant to CDMO Avara in 2016, it was touted as a lifeline for the drugmaker’s 210 on-site employees who faced termination. Three years later, with the plant ba2019/7/22